Company Description
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease.
The company was incorporated in 1998 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 730 |
| CEO | Joseph Belanoff |
Contact Details
Address: 101 Redwood Shores Parkway Redwood City, California 94065 United States | |
| Phone | 650 327 3270 |
| Website | corcept.com |
Stock Details
| Ticker Symbol | CORT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001088856 |
| CUSIP Number | 218352102 |
| ISIN Number | US2183521028 |
| Employer ID | 77-0487658 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, Chief Executive Officer and Director |
| Atabak Mokari | Chief Financial Officer and Treasurer |
| Sean Maduck | President of Endocrinology |
| Dr. William Guyer Pharm.D. | Chief Development Officer |
| Gary Charles Robb J.D. | Chief Business Officer and Secretary |
| Joseph Douglas Lyon | Chief Technology and Accounting Officer |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer |
| Amy Flood | Chief Human Resources and Communications Officer |
| Monica Tellado | President of Emerging Markets |
| Roberto W. Vieira | President of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2026 | 8-K | Current Report |
| Jun 16, 2026 | 144 | Filing |
| Jun 16, 2026 | 144 | Filing |
| Jun 3, 2026 | 8-K | Current Report |
| Jun 2, 2026 | 144 | Filing |
| Jun 1, 2026 | 144 | Filing |
| Jun 1, 2026 | 144 | Filing |
| May 29, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 28, 2026 | 8-K | Current Report |
| May 27, 2026 | 144 | Filing |